Literature DB >> 19672273

Iron chelation therapy in myelodysplastic syndrome - Cui bono?

A Tefferi, R M Stone.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19672273     DOI： 10.1038/leu.2009.39

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  7 in total

1.  Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging.

Authors:  Emanuela Messa; Sonia Carturan; Chiara Maffè; Marisa Pautasso; Enrico Bracco; Antonella Roetto; Francesca Messa; Francesca Arruga; Ilaria Defilippi; Valentina Rosso; Chiara Zanone; Antonia Rotolo; Elisabetta Greco; Rosa M Pellegrino; Daniele Alberti; Giuseppe Saglio; Daniela Cilloni
Journal:  Haematologica       Date:  2010-06-09       Impact factor: 9.941

2.  Myelodysplastic syndromes--many new drugs, little therapeutic progress.

Authors:  Ayalew Tefferi
Journal:  Mayo Clin Proc       Date:  2010-09-22       Impact factor: 7.616

Review 3.  The relevance of iron overload and the appropriateness of iron chelation therapy for patients with myelodysplastic syndromes: a dialogue and debate.

Authors:  David P Steensma
Journal:  Curr Hematol Malig Rep       Date:  2011-06       Impact factor: 3.952

Review 4.  Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management".

Authors:  Mrinal M Patnaik; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2019-01-24       Impact factor: 10.047

5.  Iron chelation therapy in myelodysplastic syndromes.

Authors:  Emanuela Messa; Daniela Cilloni; Giuseppe Saglio
Journal:  Adv Hematol       Date:  2010-06-20

Review 6.  Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management.

Authors:  Mrinal M Patnaik; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2017-03       Impact factor: 10.047

7.  A European survey on the detection and management of iron overload in transfusion-dependent patients with MDS.

Authors:  Aristoteles Giagounidis; Susanna Leto di Priolo; Susanne Ille; Pierre Fenaux
Journal:  Ann Hematol       Date:  2011-02-16       Impact factor: 3.673
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.